Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Six refractory lupus patients treated with rituximab: a case series.

× No keyword cloud information.

9 in total

1. Safety and efficacy of rituximab in refractory pediatric systemic lupus erythematosus nephritis: a single-center experience of Northern Greece.

Authors: Maria Trachana; Artemis Koutsonikoli; Evagelia Farmaki; Nikoleta Printza; Vasiliki Tzimouli; Fotios Papachristou
Journal: Rheumatol Int Date: 2011-11-19 Impact factor: 2.631

2. Safety and efficacy of combined cyclophosphamide and rituximab treatment in recalcitrant childhood lupus.

Authors: Ashwaq Ale'ed; Abdullah Alsonbul; Sulaiman M Al-Mayouf
Journal: Rheumatol Int Date: 2013-11-12 Impact factor: 2.631

3. Available evidence and outcome of off-label use of rituximab in clinical practice.

Authors: I Danés; A Agustí; A Vallano; J Martínez; C Alerany; A Ferrer; A López; J Cortés-Hernández; J A Bosch
Journal: Eur J Clin Pharmacol Date: 2013-05-23 Impact factor: 2.953

4. Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome.

Authors: Catherine Melander; Marion Sallée; Pierre Trolliet; Sophie Candon; Xavier Belenfant; Eric Daugas; Phillipe Rémy; Virginie Zarrouk; Evangéline Pillebout; Christian Jacquot; Jean-Jacques Boffa; Alexandre Karras; Virginie Masse; Philippe Lesavre; Caroline Elie; Isabelle Brocheriou; Bertrand Knebelmann; Laure-Hélène Noël; Fadi Fakhouri
Journal: Clin J Am Soc Nephrol Date: 2009-03-04 Impact factor: 8.237

5. Treatment of vitiligo with a chimeric monoclonal antibody to CD20: a pilot study.

Authors: A Ruiz-Argüelles; M García-Carrasco; G Jimenez-Brito; S Sánchez-Sosa; B Pérez-Romano; J Garcés-Eisele; C Camacho-Alarcón; V Reyes-Núñez; M Sandoval-Cruz; C Mendoza-Pinto; A López-Colombo
Journal: Clin Exp Immunol Date: 2013-11 Impact factor: 4.330

Review 6. The potential utility of B cell-directed biologic therapy in autoimmune diseases.

Authors: D G Arkfeld
Journal: Rheumatol Int Date: 2007-10-24 Impact factor: 2.631

7. Efficacy of Rituximab in a Systemic Lupus Erythematosus Patient Presenting with Diffuse Alveolar Hemorrhage.

Authors: Gabriela Montes-Rivera; Grissel Ríos; Luis M Vilá
Journal: Case Rep Rheumatol Date: 2017-11-15

Review 8. Off-label use of rituximab in systemic lupus erythematosus: a systematic review.

Authors: Eleanor Murray; Martin Perry
Journal: Clin Rheumatol Date: 2010-02-13 Impact factor: 2.980

9. Rituximab therapy for juvenile-onset systemic lupus erythematosus.

Authors: Obioma Nwobi; Carolyn L Abitbol; Jayanthi Chandar; Wacharee Seeherunvong; Gastón Zilleruelo
Journal: Pediatr Nephrol Date: 2007-12-19 Impact factor: 3.714

9 in total